Financial Results and Pipeline Progress in Focus for Pharvaris
PHARVARIS NV (NASDAQ:PHVS), a late-stage biopharmaceutical company, has reported its financial results for the fourth quarter and full year ended December 31, 2025. The report provides a detailed update on the company’s clinical pipeline and financial position as it advances its lead candidate, deucrictibant, for bradykinin-mediated angioedema.
Earnings and Revenue Versus Estimates
As a clinical-stage company with no commercial products, Pharvaris does not generate revenue. This was reflected in the reported figures, which aligned with analyst expectations.
- Q4 2025 Revenue: Reported €0.0 million, matching the analyst estimate of €0.0 million.
- Q4 2025 EPS: Reported a loss per share of €0.72. This was wider than the analyst consensus estimate for a loss of €0.6333 per share.
The wider-than-expected quarterly loss is attributable to increased research and development spending as the company advances multiple pivotal clinical trials. For the full year 2025, the company reported a net loss of €176 million, or €2.97 per share, compared to a loss of €134 million, or €2.48 per share, in 2024.
Market Reaction and Financial Position
The market's initial reaction to the earnings release appears measured, with the stock showing modest positive movement in the near term. The company’s robust cash position is likely a key factor providing stability. Pharvaris reported cash and cash equivalents of €292 million as of December 31, 2025, a slight increase from €281 million at the end of 2024. Management emphasized operating in a "financially disciplined manner," and this liquidity is expected to fund operations through several upcoming clinical and regulatory milestones.
Key Business Updates from the Report
The financial update was accompanied by significant progress across the company’s development pipeline for deucrictibant, an oral bradykinin B2 receptor antagonist.
- CHAPTER-3 Trial Completion: Enrollment has been completed in the pivotal CHAPTER-3 Phase 3 study evaluating deucrictibant extended-release (XR) for the prophylactic treatment of hereditary angioedema (HAE) attacks. Topline data from this study is anticipated in the third quarter of 2026.
- NDA Submission on Track: The company reaffirmed its timeline to submit a New Drug Application (NDA) to the U.S. FDA for deucrictibant immediate-release (IR) for the on-demand treatment of HAE attacks in the first half of 2026. This submission will be based on data from the successful RAPIDe-3 and RAPIDe-2 Phase 3 studies.
- Expansion into Additional Indications: Enrollment is ongoing in the CREAATE study, a pivotal Phase 3 trial evaluating deucrictibant for both prophylactic and on-demand treatment of acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
- Upcoming Investor Presentations: The company is scheduled to present at the BofA Securities Health Care Conference in May 2026 and the RBC Capital Markets Global Healthcare Conference later the same month.
Looking Ahead
The provided analyst estimates for 2026 reflect the company’s ongoing pre-revenue status, with no sales projected for the first quarter or the full year. The primary focus for investors remains squarely on clinical and regulatory execution. The anticipated NDA submission in the coming months and the CHAPTER-3 data readout in late 2026 represent the most significant near-term catalysts for the company.
For a detailed review of historical earnings and future analyst projections, you can view the earnings history and analyst estimates for Pharvaris.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, an endorsement, or a recommendation to buy, sell, or hold any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.